+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping



Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping



Journal of Molecular Diagnostics 13(1): 64-73



KRAS and BRAF mutations predict the resistance of colorectal carcinomas to therapy targeted to the epidermal growth factor receptor, but their detection can be challenging because of high testing volume, frequently low tumor content, and the spectrum of rarer mutations in these genes. To address these issues, we evaluated a locked nucleic acid (LNA)-PCR sequencing assay to detect low levels of mutant DNA, and we also evaluated a mass spectrometry genotyping assay (Sequenom, San Diego, CA) that is suitable for broad mutation screening. Clinical cases (n = 308) previously tested for KRAS and BRAF by standard sequencing were retested by LNA-PCR sequencing incorporating an LNA oligonucleotide to suppress amplification of nonmutant DNA, and by a Sequenom assay panel targeting common mutations in both genes. Standard sequencing detected 121 KRAS (39%) and 10 BRAF mutations; retesting with the LNA-based method and the Sequenom assay detected 19 (140/308, 45%) and 6 (127/308, 41%) additional KRAS mutants, respectively. One additional BRAF mutant was detected by the Sequenom assay. The analytical sensitivities were 0.3% for both KRAS and BRAF by LNA-PCR and from 1% to 10% for the Sequenom assays, depending on the specific mutation. Given these results, standard sequencing is suboptimal for mutation detection in metastatic and treated lesions even with predissection for tumor enrichment. High-sensitivity LNA-PCR sequencing detects significantly more mutations, whereas the Sequenom platform shows intermediate sensitivity but offers significant advantages for broader mutation screening.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052517181

Download citation: RISBibTeXText

PMID: 21227396

DOI: 10.1016/j.jmoldx.2010.11.005


Related references

Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathology, Research and Practice 207(12): 762-768, 2012

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clinical Endocrinology 64(1): 105-109, 2006

Locked nucleic acid probe enhances Sanger sequencing sensitivity and improves diagnostic accuracy of high-resolution melting-based KRAS mutational analysis. Clinica Chimica Acta; International Journal of Clinical Chemistry 457(): 75-80, 2016

Detection of KRAS,NRAS and BRAF gene mutations in colorectal carcinoma. Zhonghua Bing Li Xue Za Zhi 44(4): 254-257, 2015

Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma. Zhonghua Bing Li Xue Za Zhi 41(9): 590-594, 2013

Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. Molecular Medicine 18: 1519-1526, 2013

BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. Journal of Pathology 214(3): 320-327, 2007

High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. American Journal of Clinical Pathology 130(2): 247-253, 2008

The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. Journal of Molecular Diagnostics 12(5): 705-711, 2011

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. Journal of Cellular and Molecular Medicine 14(8): 2122-2131, 2011

Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 11(8): 1169-1179, 2010

A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations: A Morphology-Based Approach in Colorectal Carcinoma. Yearbook of Pathology and Laboratory Medicine 2011: 319-320, 2011

A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. Journal of Molecular Diagnostics 12(3): 292-299, 2010

KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics. Journal of Molecular Diagnostics 15(3): 299-311, 2013

KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26(1): 158-163, 2006